260 related articles for article (PubMed ID: 26378211)
21. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors.
Schreuder M; Jourdi G; Veizaj D; Poole DA; Cheung KL; Poenou G; Verhoef D; Thomassen S; Janssen LFH; Stepanian A; Hackeng TM; Gaussem P; Reitsma PH; Geerke DP; Siguret V; Bos MHA
J Thromb Haemost; 2024 May; ():. PubMed ID: 38729577
[TBL] [Abstract][Full Text] [Related]
22. [Not Available].
Ekenberg LF; Lindgren LM; Pehrson C
Ugeskr Laeger; 2024 May; 186(22):. PubMed ID: 38847299
[TBL] [Abstract][Full Text] [Related]
23. Preventing Bleeding With Direct-Acting Oral Anticoagulants.
Schwartz JB; Kogan SC; Fang MC
J Am Coll Cardiol; 2021 Oct; 78(16):e127. PubMed ID: 34649705
[No Abstract] [Full Text] [Related]
24. Factor Xa--a promising target for drug development.
Kaiser B
Cell Mol Life Sci; 2002 Feb; 59(2):189-92. PubMed ID: 11915937
[No Abstract] [Full Text] [Related]
25. Back to the Future: Observational Studies and Anticoagulant Selection for Nonvalvular Atrial Fibrillation.
Gattellari M
Stroke; 2024 May; 55(5):1171-1173. PubMed ID: 38511348
[No Abstract] [Full Text] [Related]
26. Factor Xa inhibitors in hemodialysis: OK-for now!
Banchs JE
Proc (Bayl Univ Med Cent); 2023; 36(6):744. PubMed ID: 37829211
[No Abstract] [Full Text] [Related]
27. Novel antidotes for target specific oral anticoagulants.
Das A; Liu D
Exp Hematol Oncol; 2015; 4():25. PubMed ID: 26380149
[TBL] [Abstract][Full Text] [Related]
28. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.
Caldeira D; Barra M; Ferreira A; Rocha A; Augusto A; Pinto FJ; Costa J; Ferreira JJ
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1239-49. PubMed ID: 26434935
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
[TBL] [Abstract][Full Text] [Related]
30. Novel anticoagulants: general overview and practical considerations for dental practitioners.
Elad S; Marshall J; Meyerowitz C; Connolly G
Oral Dis; 2016 Jan; 22(1):23-32. PubMed ID: 26386350
[TBL] [Abstract][Full Text] [Related]
31. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
32. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.
Cuker A
J Thromb Thrombolysis; 2016 Feb; 41(2):241-7. PubMed ID: 26386967
[TBL] [Abstract][Full Text] [Related]
33. Management of Bleeding Associated with New Oral Anticoagulants.
Franchini M; Bonfanti C; Mannucci PM
Semin Thromb Hemost; 2015 Oct; 41(7):788-801. PubMed ID: 26408923
[TBL] [Abstract][Full Text] [Related]
34. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
36. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.
Chan NC; Bhagirath V; Dale BJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2015 Nov; 13(11):1213-23. PubMed ID: 26471327
[TBL] [Abstract][Full Text] [Related]
37. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
38. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
[TBL] [Abstract][Full Text] [Related]
39. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
40. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
